Literature DB >> 8020666

Lipolytic activity of bacterial lipase survives better than that of porcine lipase in human gastric and duodenal content.

M Raimondo1, E P DiMagno.   

Abstract

BACKGROUND/AIMS: Treatment of pancreatic steatorrhea with porcine lipase is unsatisfactory because it is rapidly denatured by acidic intraluminal conditions. The aim of this study was to determine if bacterial lipase is resistant to acid denaturation and is active in the presence of bile acids by comparing its stability with that of porcine lipase in gastric and duodenal juice obtained from six patients undergoing a cholecystokinin octapeptide pancreatic function test.
METHODS: After inactivating native lipolytic activity, both juices were altered to simulate fasting and postprandial conditions in normal patients and patients with pancreatic insufficiency. Gastric juice was adjusted to pH 2, 3, 4, or 6, duodenal juice to pH 4 or 6, and bile acid concentrations to 4 or 12 mmol/L. Nutrients were added to one half of the samples. Initial bacterial or porcine lipolytic concentrations were 25 or 250 U/mL. After a 1-hour incubation at 37 degrees C, lipolytic activity was remeasured.
RESULTS: In gastric juice, more bacterial lipolytic activity survived than porcine lipolytic activity at both concentrations in the absence of nutrients and at a concentration of 25 U/mL with nutrients (P < 0.05). In duodenal juice, more bacterial lipolytic activity survived than porcine activity at pH 4 under all test conditions (P < 0.05).
CONCLUSIONS: Bacterial lipolytic activity should survive better within the gastrointestinal lumen than porcine lipolytic activity and be more effective to treat steatorrhea.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8020666     DOI: 10.1016/0016-5085(94)90081-7

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  6 in total

Review 1.  Pancreatic enzyme replacement therapy.

Authors:  P Layer; J Keller; P G Lankisch
Journal:  Curr Gastroenterol Rep       Date:  2001-04

Review 2.  Human pancreatic exocrine response to nutrients in health and disease.

Authors:  J Keller; P Layer
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

Review 3.  Treatment of pancreatic exocrine deficiency.

Authors:  Martin Sarner
Journal:  World J Surg       Date:  2003-10-13       Impact factor: 3.352

4.  Artificial Cell Therapy: New Strategies for the Therapeutic Delivery of Live Bacteria.

Authors:  Satya Prakash; Mitchell Lawrence Jones
Journal:  J Biomed Biotechnol       Date:  2005

5.  Nanofibrous Formulation of Cyclodextrin Stabilized Lipases for Efficient Pancreatin Replacement Therapies.

Authors:  Gergő Dániel Tóth; Adrienn Kazsoki; Benjámin Gyarmati; András Szilágyi; Gábor Vasvári; Gábor Katona; Lajos Szente; Romána Zelkó; László Poppe; Diána Balogh-Weiser; György T Balogh
Journal:  Pharmaceutics       Date:  2021-06-27       Impact factor: 6.321

6.  Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis.

Authors:  Devi Mukkai Krishnamurty; Atoosa Rabiee; Sanjay B Jagannath; Dana K Andersen
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.